Following a bit of reverse lobbying, or what Pfizer Inc. CEO Ian Read characterized as "an extensive discussion" with U.S. President Donald Trump, the New York-based company said it would hold off on midyear price increases that went into effect July 1 to give Trump more time to work on his blueprint to strengthen the health care system and improve access for patients.